▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #88 by analyst upside · 2026-06-27
ALGS
Aligos Therapeutics, Inc.
Healthcare · Market Cap $34M · P/E 0x
ANALYST PRICE TARGET
+910.5%
implied upside to consensus target
Current Price $5.57
Consensus Target $56.29
Bull Target $175.0
Bear Target $20.0
Analysts Covering 7
ANALYST CONSENSUS — BUY
Strong Buy
1
Buy
6
Hold
0
Sell
0
52-Week Low $4.8
52-Week High $13.69
YTD Return -39.0%
FUNDAMENTALS
Market Cap $34M
P/E Ratio (TTM) N/A
Forward P/E -1.4x
EPS (TTM) $-9.78
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $5M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $4.8
52-Week High $13.69
Current Price $5.57
Bear Target $20.0
Bull Target $175.0
● Now $5.57 ● Target $56.29
TRADING DATA
Avg Volume 213K
YTD Return -39.0%
Analyst Count 7
Consensus Buy
Upside to Target +910.5%
Last Updated 2026-06-27

ANALYST SUMMARY

Aligos Therapeutics, Inc. (ALGS) is currently trading at $5.57 with a Wall Street consensus price target of $56.29, implying potential upside of 910.5% over the next 12 months. 7 analysts currently cover ALGS, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $175.0, while the most cautious has a target of $20.0.

ALGS operates in the Healthcare sector with a market capitalisation of $34M. The stock is down 39.0% year-to-date and is currently trading near the lower end of its 52-week range of $4.8 – $13.69.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

PSTV +757.1%
Plus Therapeutics, Inc.
$29M · P/E 0.2x · Buy
DWTX +748.5%
Dogwood Therapeutics, Inc.
$55M · P/E 1.4x · Strong Buy
ETST +566.7%
Earth Science Tech, Inc.
$43M · P/E 15.0x · Hold
VXRT +488.2%
Vaxart, Inc.
$123M · P/E 3.2x · Buy
AGEN +411.6%
Agenus Inc.
$126M · P/E 1.4x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for ALGS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Lake Street ● Initiated
Buy 2026-05-28 27% win rate (11 calls)
Cantor Fitzgerald ● Initiated
Overweight 2026-05-21 40% win rate (10 calls)
WestPark Capital ● Initiated
Buy 2026-03-26 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-03-11 31% win rate (48 calls)
UBS ● Initiated
Buy 2026-01-07 33% win rate (6 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-09-12 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-03-31 31% win rate (48 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2025-03-11 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →